Key Highlights

  • Parabolic Technologies, Inc. (NASDAQ:PARA) sank 41.94% after pricing a USD 13.5 million underwritten offering on November 4, 2026, reported as 4.96 million units at USD 2.72 each, with warrants attached.
  • Cenntro Inc. (NASDAQ:CENN) lost 27.12% and Innventure dropped 29.01%, and each has an at-the-market program in place, USD 100 million at Cenntro and up to USD 60 million at Innventure.
  • Antelope Enterprise Holdings Limited (NASDAQ:AEHL) gained 78.63% even though it signed a USD 100 million ATM deal with D. Boral Capital on October 1, 2026, and it also carries discounted convertible notes.
  • Precision BioSciences (NASDAQ:DTIL) advanced 17.49% to about USD 9.54 after setting terms for roughly USD 125 million of stock at USD 7.75 a share, covering 10,235,077 shares plus pre-funded warrants.

Parabolic Technologies, Inc. (NASDAQ:PARA): An Underwritten Offering Bundled With Warrants

The steepest drop, 41.94% to USD 0.1852 in trading on November 5, 2026 according to published market data, hit Parabolic Technologies, Inc. (NASDAQ:PARA), formerly Banzai International, a day after it priced a USD 13.5 million underwritten public offering. Published coverage cites 4.96 million units at USD 2.72, each bundling warrants exercisable at USD 6.80, though those terms rest on coverage rather than a final prospectus. In an underwritten deal, an Investment bank buys the units and resells them, so proceeds depend on closing, and pricing is usually set at a discount. Units add new shares and warrants, and warrants can add more shares if exercised, so each holder owns a smaller slice. Shareholders also approved lifting authorized shares from 350 million to 850 million, leaving room for further issuance. The quoted price sits far below the unit price, a gap that published market data does not explain. Nasdaq has also issued a delisting determination, and cumulative reverse splits total 1-for-2,000. With about 11.7 million shares traded, quoted moves can reverse.

Cenntro Inc. (NASDAQ:CENN): A USD 100 Million Ceiling Set Against a Very Small Valuation

At Cenntro Inc. (NASDAQ:CENN), the 27.12% decline to about USD 0.129 on 3.79 million shares followed an at-the-market program of up to USD 100 million, carrying a 3.5% commission, disclosed on October 9, 2026, a few weeks after a private Placement of about USD 57.0 million closed in mid-September. Such a program sells new shares into the open market at prevailing prices, which raises cash but dilutes holders, and the company has not said how much it has sold. Published market data puts Market Value near USD 2.27 million, far below the program ceiling, and the quoted price is well under the USD 3.90 close of October 8, 2026, a gap the filings reviewed do not reconcile. A 1-for-60 reverse split in April 2026 restored bid price compliance on April 28, 2026. Second quarter Revenue was about USD 6.2 million against a net loss of about USD 10.6 million, with cash near USD 4.3 million at June 30, 2026. A third quarter report had not been located. A small float means quoted moves can reverse.

Antelope Enterprise Holdings Limited (NASDAQ:AEHL): A Rally Despite Two Financing Instruments

The 78.63% gain at Antelope Enterprise Holdings Limited (NASDAQ:AEHL), to USD 11.20, arrived without a company announcement located for November 5, 2026, even though two financing tools are in place. On October 1, 2026 the company signed a deal with D. Boral Capital for an at-the-market program of up to USD 100 million of Class A shares, with proceeds for general corporate purposes. In September 2026 it closed USD 6.0 million of 8.00% convertible notes, with net proceeds of about USD 5.965 million. The notes convert at 80% of the lowest daily volume-weighted average price over three trading days, subject to a Nasdaq 19.99% cap and a registration limit of 12,000,000 shares, so holders profit by converting and selling at a discount. Cash was reported near USD 1.78 million, small against the program size, while first-half revenue fell to USD 29.9 million from USD 48.7 million. A 1-for-16 reverse split on August 7, 2026 left about 1,309,197 shares. Published coverage describes an October 14, 2026 spike to about USD 30.60 that closed near USD 11.49.

Innventure, Inc. (NASDAQ:INV): Funding Pressure Underneath a Share Sale Program

At Innventure, Inc. (NASDAQ:INV), the 29.01% fall to about USD 0.1534 on 4.52 million shares came only days after the company formed a Strategic Review Committee on November 2, 2026, which cited near-term Liquidity needs at the parent company. On October 6, 2026 the company established an at-the-market program of up to USD 60 million, as an alternative to a USD 75 million Equity purchase agreement from 2023, and it said it does not plan to use the program for Accelsius at current prices or to raise the full amount. The standby agreement remains another route that keeps dilution possible. The committee oversees interim funding for AeroFlexx, which is pursuing a sale or interim third-party financing, and for Refinity, which is funded through year-end. Accelsius, which holds most of the consolidated cash, has engaged Evercore Group to explore private capital. Headcount has dropped from 40 to 15 since the end of the first quarter. The release gave no Debt or total cash figures, so results due November 12, 2026 will be the first full look, and with a market value near USD 13.31 million, quoted moves can reverse.

Precision BioSciences (NASDAQ:DTIL): A Sizable Raise Coinciding With a Share Gain

The 17.49% gain at Precision BioSciences (NASDAQ:DTIL), to about USD 9.54 on Volume 5.79 times normal, came as the company priced an underwritten offering of about USD 125 million at USD 7.75 per share on November 5, 2026, with closing expected on or about November 6, 2026. It covers 10,235,077 common shares plus pre-funded warrants for up to 5,893,964 shares, priced at USD 7.749995, with TD Cowen and Guggenheim Securities as lead managers. A pre-funded Warrant lets an investor pay nearly the full price up front and exercise later for a nominal sum, which helps holders stay under an ownership threshold. Simple arithmetic gives roughly 16.1 million new shares and USD 125 million, close to half of the USD 266.51 million market value in published market data, so dilution is material. Proceeds are earmarked for PBGENE-HBV and PBGENE-DMD, along with general corporate purposes. The company did not explain why shares rose despite the raise, so that reason remains unconfirmed. Gene editing carries trial and regulatory risks, and a quoted intraday gain can reverse.

Where Things Stand

Share sales and standing programs weaken the stakes of current owners, and the weight of evidence suggests the market response depends on how big the raise is against the company, how proceeds get used and who the buyers are. Parabolic Technologies, Inc. (NASDAQ:PARA) fell on an underwritten deal and a delisting determination. Cenntro Inc. (NASDAQ:CENN) declined under a standing program. Innventure, Inc. (NASDAQ:INV) fell with another program in place. Antelope rose despite one, and Precision BioSciences rose after a sizable placement with specialist investors. Nothing here implies a continued move in either direction. Upcoming markers include the Nasdaq hearing, the Innventure results on November 12, 2026, the closing of the Precision BioSciences (NASDAQ:DTIL) offering and disclosures on at-the-market usage.